The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services
A legfontosabb adatok
- Hol
- Toronto (Kanada)Mind a 3 helyszín megnézése
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiket genetikai vizsgálatra utaltak, valamint olyan gyermekek szüleit vagy törvényes gyámját, akiket genetikai vizsgálatra utaltak. A vizsgálat egy digitális platformot tesztel, amely végigvezeti az embereket a genetikai vizsgálaton.
- Életkor
- 18 éves vagy idősebb
- Nem
- Mindkét nem részt vehet.
A részvétel fő kizáró okai
- Ismert, hogy Ontarióban nem végezhető rajta klinikai genetikai vizsgálat
- Sürgős klinikai genetikai vizsgálatra van szüksége
- Születés előtti genetikai vizsgálatra van szüksége
- Nem beszél és nem olvas folyékonyan angolul
Gépi kiolvasás: 2026. november 12.
Helyszínek itt: Kanada
- Mount Sinai HospitalToronto, KanadaContact: Marc Clausen, MARésztvevőt keres
- Sunnybrook HospitalToronto, KanadaContact: Marc Clausen, MARésztvevőt keres
- The Hospital for Sick ChildrenToronto, KanadaContact: Stephanie Luca, MARésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Unity Health Toronto
- Azonosító
- NCT06455384
- A regiszteradat frissítve
- 2026. június 24.
- Eredeti leírás
Genetic testing (GT) (including targeted panels, exome and genome sequencing) is increasingly being used for patient care as it improves diagnosis and health outcomes. In spite of these benefits, genetic testing is a complex and costly health service. This results in unequal access, increased wait times and inconsistencies in care. The use of e-health tools to support genetic testing delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to receive and act on medical results. We have previously developed and tested an interactive, adaptable and patient-centred digital decision support tool (Genetics ADvISER) to be used for genetic testing decision making, and have now developed the Genetics Navigator (GN), a patient-centred e-health navigation platform for end-to-end genetic service delivery. The objective of this study is to evaluate the effectiveness of the GN in an RCT in reducing distress with patients and parents of patients being offered genetic testing. Results of this trial will be used to establish whether the GN is effective to use in practice. If effective, GN could fill a critical clinical care gap and improve health outcomes and service use by reducing counselling burden as well as overuse, underuse and misuse of services. These are concerns policy makers seek to address through the triple aims of health care1. This study represents a significant advance in personalized health by assessing the effectiveness of this novel, comprehensive e-health platform to ultimately improve genetic service delivery, accessibility, patient experiences, and patient outcomes.A teljes eredeti leírásKevesebb
Genetic testing (GT) (including targeted panels, exome and genome sequencing) is increasingly being used for patient care as it improves diagnosis and health outcomes. In spite of these benefits, genetic testing is a complex and costly health service. This results in unequal access, increased wait times and inconsistencies in care. The use of e-health tools to support genetic testing delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to receive and act on medical results. We have previously developed and tested an interactive, adaptable and patient-centred digital decision support tool (Genetics ADvISER) to be used for genetic testing decision making, and have now developed the Genetics Navigator (GN), a patient-centred e-health navigation platform for end-to-end genetic service delivery. The objective of this study is to evaluate the effectiveness of the GN in an RCT in reducing distress with patients and parents of patients being offered genetic testing. Results of this trial will be used to establish whether the GN is effective to use in practice. If effective, GN could fill a critical clinical care gap and improve health outcomes and service use by reducing counselling burden as well as overuse, underuse and misuse of services. These are concerns policy makers seek to address through the triple aims of health care1. This study represents a significant advance in personalized health by assessing the effectiveness of this novel, comprehensive e-health platform to ultimately improve genetic service delivery, accessibility, patient experiences, and patient outcomes.
Inclusion:; Adult patients (18 years of age or older) who are referred to participating clinicians at Mount Sinai Hospital for clinical genetic testing; Parents/legal guardians (18 years of age or older) of pediatric patients who are referred to participating clinicians at SickKids for clinical genetic testing; Exclusion:; Known not to be eligible for clinical genetic testing in Ontario; Requires urgent clinical genetic testing or prenatal genetic testing; Not fluent in English (speaking and reading).